NIAID and NIH fund Crucell's Ebola and Marburg programme
This article was originally published in Scrip
Executive Summary
Crucellhas signed a contract with the US National Institute of Allergy and Infectious Diseases, part of theNational Institutes of Health, which will provide up to $30 million in funding to develop its multivalent filovirus vaccine to protect against both the Ebola and Marburg viruses. Crucell may receive a further $40 million if the NIH triggers certain additional options. The contract, which makes use of Crucell's AdVac vaccine technology, builds upon the existing relationship between the two parties, which signed a $16.2 million contract in 2006 for the use of live viral vectors for the design and development of a HIV vaccine (Scrip Online, October 10th, 2006).